Trial Profile

Metabolic Effects of Antipsychotic Substitution in Children.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II/III

Latest Information Update: 08 May 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aripiprazole (Primary) ; Olanzapine (Primary) ; Risperidone (Primary)
Indications Affective disorders; Anxiety disorders; Asperger syndrome; Attention deficit and disruptive behaviour disorders; Autistic disorder; Bipolar disorders; Conduct disorder; Depressive disorders; Generalised anxiety disorder; Gilles de la Tourette's syndrome; Major depressive disorder; Mood disorders; Movement disorders; Obsessive-compulsive disorders; Pervasive child development disorders; Psychotic disorders; Schizophrenia; Social phobia; Tic disorders
Focus Adverse reactions
Acronyms SMEAC

Most Recent Events

20 Nov 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov
06 Jun 2009 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com